StockData
Ensysce Biosciences, Inc. logo

Ensysce Biosciences, Inc. (ENSC) stock

ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.38−0.03 (-6.28%)

Close on Nov 17, 2026Market cap $7.47MP/E –Yield –

Ensysce Biosciences cash

Cash and short-term investments held at the end of each period.

Ensysce Biosciences's cash was $676.70K at Jun 30, 2026. For fiscal 2025 it was $4.31M, up 23.1% from the year before. The highest annual figure on record is $12.26M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.31M+23.1%
FY2024Dec 31, 2024$3.50M+211.7%
FY2023Dec 31, 2023$1.12M-64.3%
FY2022Dec 31, 2022$3.15M-74.3%
FY2021Dec 31, 2021$12.26M+6215.1%
FY2020Dec 31, 2020$194.21K-81.7%
FY2019Dec 31, 2019$1.06M-36.0%
FY2018Dec 31, 2018$1.66M-20.7%
FY2017Dec 31, 2017$2.09M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$676.70K-69.4%
Q1 FY2026Mar 31, 2026$745.48K-75.6%
Q4 FY2025Dec 31, 2025$4.31M+23.1%
Q3 FY2025Sep 30, 2025$1.67M-59.7%
Q2 FY2025Jun 30, 2025$2.21M+112.0%
Q1 FY2025Mar 31, 2025$3.05M-10.3%
Q4 FY2024Dec 31, 2024$3.50M+211.7%
Q3 FY2024Sep 30, 2024$4.15M+183.6%
Q2 FY2024Jun 30, 2024$1.04M-72.8%
Q1 FY2024Mar 31, 2024$3.40M+140.5%
Q4 FY2023Dec 31, 2023$1.12M-64.3%
Q3 FY2023Sep 30, 2023$1.46M-67.5%
Q2 FY2023Jun 30, 2023$3.83M+2.5%
Q1 FY2023Mar 31, 2023$1.42M-83.2%
Q4 FY2022Dec 31, 2022$3.15M-74.3%
Q3 FY2022Sep 30, 2022$4.50M-34.2%
Q2 FY2022Jun 30, 2022$3.73M-53.4%
Q1 FY2022Mar 31, 2022$8.44M+46705.8%
Q4 FY2021Dec 31, 2021$12.26M+6215.1%
Q3 FY2021Sep 30, 2021$6.85M+12697.6%
Q2 FY2021Jun 30, 2021$8.01M+6367.2%
Q1 FY2021Mar 31, 2021$18.03K-89.3%
Q4 FY2020Dec 31, 2020$194.21K-81.7%
Q3 FY2020Sep 30, 2020$53.49K-95.8%
Q2 FY2020Jun 30, 2020$123.88K-91.2%
Q1 FY2020Mar 31, 2020$167.95K-88.9%
Q4 FY2019Dec 31, 2019$1.06M-36.0%
Q3 FY2019Sep 30, 2019$1.27M-27.4%
Q2 FY2019Jun 30, 2019$1.40M-18.6%
Q1 FY2019Mar 31, 2019$1.51M-20.8%
Q4 FY2018Dec 31, 2018$1.66M-20.7%
Q3 FY2018Sep 30, 2018$1.75M–
Q2 FY2018Jun 30, 2018$1.72M–
Q1 FY2018Mar 31, 2018$1.90M–
Q4 FY2017Dec 31, 2017$2.09M–

More Ensysce Biosciences figures

See a number that looks wrong?